Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children

Burosumab (KRN23) is an FGF23 neutralizing antibody that has been the subject of several recent clinical trials principally focused on the treatment of hypophosphatemic rickets in patients with X-linked hypophosphatemia (XLH). Since the first publications in 2014, these trials have demonstrated effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schindeler, Aaron, Biggin, Andrew, Munns, Craig F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271822/
https://www.ncbi.nlm.nih.gov/pubmed/32547492
http://dx.doi.org/10.3389/fendo.2020.00338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271822/
https://www.ncbi.nlm.nih.gov/pubmed/32547492
http://dx.doi.org/10.3389/fendo.2020.00338

Ejemplares similares